Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.560
-0.020 (-3.45%)
At close: Feb 21, 2025, 4:00 PM
0.562
+0.002 (0.43%)
After-hours: Feb 21, 2025, 6:21 PM EST
Adaptimmune Therapeutics Employees
Adaptimmune Therapeutics had 449 employees as of December 31, 2023. The number of employees decreased by 85 or -15.92% compared to the previous year.
Employees
449
Change (1Y)
-85
Growth (1Y)
-15.92%
Revenue / Employee
$389,846
Profits / Employee
-$99,145
Market Cap
143.17M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ADAP News
- 23 days ago - Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Newsfile Corp
- 5 weeks ago - Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) - Newsfile Corp
- 2 months ago - Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK - Newsfile Corp
- 2 months ago - First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) - Newsfile Corp
- 3 months ago - Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Adaptimmune Reports Q3 2024 Financial and Business Updates - Newsfile Corp
- 3 months ago - Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial - Newsfile Corp
- 3 months ago - Adaptimmune to Participate in Scientific and Medical Conferences this November and December - Newsfile Corp